Pharmacology
Mycophenolate mofetil (MMF) is an ester prodrug tial interest in organ transplantation is the inhibitory with higher bioavailability than the active agent, effect of MPA on the proliferation of human arterial mycophenolic acid (MPA).1 MPA inhibits inosine smooth muscle cells in vitro. Arterial disease plays monophosphate (IMP) dehydrogenase, an enzyme a central role in chronic graft rejection, holding out that facilitates the conversion of IMP to xanthosine hope for additional benefit from the use of MMF.18 monophosphate, a precursor of guanine nucleotides.
In vivo MMF inhibits the graft coronary artery disease This is an important step in the de novo pathway of of rat cardiac allografts19 and cynomologous monkeypurine nucleotide synthesis on which lymphocytes to-baboon cardiac xenografts20 and it attenuates primarily depend, unlike neutrophils, for example. 2 functional, morphological and immunohistochemical In addition, different isoforms of IMP dehydrogenase changes associated with chronic rejection in rat renal exist, and MPA is not only almost five times more allografts. 21 Finally, in a rat model of progressive potent in inhibiting the type II isoform, that is renal injury following 5/6 renal ablation, MMF was associated with stimulated rather than resting shown to limit a process that is not primarily lymphocytes,3 but is also, to some extent, cell type immunological.22 specific. 4 Thus, on theoretical grounds, MMF represAlso of interest is the observation that the use ents a significant improvement on the antimetabolite of MMF is associated with the induction of azathioprine the use of which is well-established in donor-specific tolerance in rat cardiac19 and mouse organ transplantation.
pancreatic islet12 allografting. The use of any immunosuppressive agent puts the patient at risk of increased infection and malignancy.
In vitro and animal studies
With respect to infection, it is of interest to note that in a study in which rats were provoked with MMF is effective in prolonging the survival of mouse Pneumocystis carinii, no animal treated with MMF and rat cardiac allografts, 5, 6 showing an additive (even in combination with dexamethasone) effect with cyclosporin, brequinar or tacrolimus. [6] [7] [8] [9] developed discernible infection, in contrast to rats It can also reverse rejection of rat cardiac allografts6 treated with either tacrolimus or sirolimus, two other and prolong canine hepatic allograft survival10 as immunosuppressive agents used in transplantation.23 well as mouse11-13 and rat14 pancreatic allograft Interestingly, no case of P. carinii has been reported survival. Finally, in a canine model, it has been in any of the clinical trials of MMF in patients in shown to prolong renal allograft survival15 and the MMF limbs of the trial, although all three major reverse acute rejection.16 Rat allograft studies have trials have found P. carinii infection in the control reported a role in reducing ischaemia-reperfusion (placebo or azathioprine) limbs.24-26 (Nor have any injury. 17 An additional experimental observation of potencases of Cryptococcus or Listeria infection been reported in these trials.) This effect on P. carinii (Banff grade II or higher) was less common in the MMF groups (6% and 10%) than in the azathioprobably results from direct toxicity to the microbe by MMF. 27 prine group (20%). Again, there was a lower use of antilymphocyte therapy in the MMF groups. A further Finally, MMF has also been demonstrated in animal models to have anti-neoplastic effects, such evaluation at 12 months in this study showed that the significant difference between the MMF groups as the inhibition of the growth of human T-cell tumours in athymic nude mice. 28 and the azathioprine group was maintained. Prophylaxis episodes. Graft loss due to rejection occurred in 6.3% of the placebo/azathioprine group and 2.6% All three of the large multicentre prospective, randomized, double-blind controlled trials of the use and 3.5% of the MMF groups (2 g/day and 3 g/day, respectively). Graft loss from any cause was 12.4%, of MMF in clinical renal transplantation have demonstrated significant benefit from use of the drug. The 9.6% and 10.8%, in the respective groups. Acute rejection (not necessarily resulting in graft loss) was European Mycophenolate Mofetil Cooperative Study Group24 reported a trial of the use of two doses 41%, 20% and 16% respectively. These findings all achieved statistical significance. In addition, a of MMF (2 g/day or 3 g/day) vs. placebo in the prevention of acute rejection within the first 6 months number of trends which did not achieve significance were noted: the severity of rejection was different in following cadaveric renal transplantation. They recruited 491 patients, all of whom also received the three limbs, with the percentage with Banff grade II or III scores being 24%, 10% and 8% corticosteroids and cyclosporin. They found that the incidence of rejection, graft loss, death or other (placebo/azathioprine, MMF 2 g/day and MMF 3 g/day respectively); ALG was used in 20%, 9% treatment failure in the first 6 months fell from 56% in the placebo group to 30% in the (better tolerated) and 5% of patients; and the MMF groups tended to have lower serum creatinine levels at 1 year. 2 g/day MMF group. The MMF groups also used significantly less antilymphocyte therapy. The
The 3-year follow-up data have now been reported for these three trials, although there is, as yet, no patients in the MMF groups also had lower serum creatinine levels at 6 months than those in the analysis of pooled data. As summarized in Table 1 , all studies show a decrease in graft loss from all placebo group (although this might be an effect of survivor bias).
causes, as well as graft loss due to rejection. The differences shown did not achieve statistical signific-A second study (the 'US trial') compared the same two doses of MMF directly with azathioprine ance. However, none of the studies was designed or powered to detect differences in these parameters at (1-2 mg/kg/day). 26 The 499 patients recruited in this study also received corticosteroids, cyclosporin and 3 years, and it would, therefore, be incorrect to conclude that these constitute a meaningful negative antilymphocyte therapy at induction. This group reported that the incidence of rejection or treatment result. Indeed, considering that all three reports show the same trends and the magnitude of the effect is failure fell from 48% in the azathioprine group to 31% in each of the MMF groups. Of the rejection consistent with what was reported at 1 year, the 3-year data are reasonably encouraging for the belief episodes, a higher percentage was classified as severe in the azathioprine group than in the MMF groups.
that MMF has a long-term benefit. It is not likely that a trial powered to detect differences of this Again, the MMF groups used much less antilymphocyte therapy.
magnitude at late time points will ever be undertaken. There has been recent interest in the use of MMF The third study, conducted in Europe, Canada and Australia (the 'Tricontinental Study'),25 also compared with tacrolimus (FK506) at induction. However, anxiety has been expressed about the potential for toxicity the same two doses of MMF directly with azathioprine (100-150 mg/day) in patients who were also with this régime. A recent report randomized 187 patients to receive either azathioprine or MMF with receiving corticosteroids and cyclosporin in the first 6 months following transplantation. This trial tacrolimus. All patients also received antilymphocyte therapy at induction and steroids. The incidence of recruited 503 patients. They found that the incidence of rejection or treatment failure fell from 50% in the acute rejection at 6 months in the MMF 2-g/day group was much lower (10%) than in the azathioazathioprine group to 38% and 35% in each of two MMF groups (2 g/day and 3 g/day, respectively).
prine group (33%), but there was no difference in toxicity.30 However, 6 months represents an As in the US trial, the incidence of severe rejection rejection during a steroid-free follow-up which of 2 g/day showed a superior risk/benefit ratio for ranged from 7 to 18 months (mean 10 months). most patients, a higher dose may be more appropriate
As well as the anxieties associated with long-term for Black patients. 31 steroid therapy, there are concerns that too many kidneys are lost as a result of chronic cyclosporin
Rescue therapy nephrotoxicity. One group described six patients MMF has also been used as 'rescue therapy' for with cyclosporin nephrotoxicity in whom it proved acute rejection in uncontrolled studies.32,33 In one possible to stop cyclosporin and change the azathiomulticentre, randomized, open-label study of 150 prine to MMF without suffering any rejection epispatients with biopsy-proven refractory rejection odes.37 Importantly, these patients showed a highly despite treatment with a biological agent (OKT3 significant fall in their serum creatinine. or ALG),34 MMF was compared with intravenous Even without frank nephrotoxicity, it has been corticosteroids plus azathioprine. All patients also shown that it is safe to reduce cyclosporin dosage received cyclosporin. The authors found that in the following the conversion from azathioprine to MMF. 6 months following enrollment, 26% of the steroids/ Burke et al. reduced cyclosporin dosage to a target trough level of 50 ng/ml in 38 patients with impaired azathioprine group suffered graft loss or death, comrenal function, and noted a significant improvement pared with 14% in the MMF group. These figures in serum creatinine at 6 months. 38 Weir et al. studied were 32% and 18% at 12 months. There was also 28 patients with declining renal function.39 Their less need for subsequent antilymphocyte therapy in dose of cyclosporin was halved and MMF was the MMF group. substituted for azathioprine. Renal function improved A double-blind study has now been reported in in 21 of these patients (75%). There were no episodes which patients experiencing biopsy-proven rejection of acute rejection in this study. were randomized to receive MMF or azathioprine One report, compatible with the animal models plus pulsed corticosteroids.35 At 6 months, there was of chronic rejection discussed above, observed that a much higher requirement for subsequent antidecreasing cyclosporin dose in the context of the lymphocyte therapy in the azathioprine group (42%) introduction of MMF was associated with a reduction than in the MMF group (17%). On the basis of these in the levels of the important fibrogenic cytokine data, several centres have started to introduce MMF TGFb.40 However, a small retrospective case-control at first rejection. study failed to demonstrate any benefit of adding MMF to maintenance immunosuppression to
Maintenance therapy
patients with established chronic rejection.41 Another potential benefit of MMF may be that it One recent report describes the safety of converallows the modification of the maintenance regimen, sion to MMF monotherapy in 13 patients with an by reducing the toxic effects of other agents. The improvement in serum creatinine.42 However, this study reports only a very short follow-up period. toxic effects of a large cumulative dose of cortico-In summary, accumulating data suggest that MMF were functioning at 1-year post-transplantation, there was no difference in 8-year survival (89%) between may have a role in the maintenance phase of the management of renal transplants.
those kidneys which had suffered no acute rejection and those which had had a mild rejection episode which had not been associated with loss of graft function. By contrast, those kidneys whose function
Significance of the effect of MMF on remained impaired following a rejection episode had the incidence of acute rejection a much lower 8-year survival rate (69%). Acute rejection is clearly not the whole story and The previously preferred end-points of trials of the efficacy of maintenance immunosuppressive drugs, better early surrogates for long-term prognosis are being developed. However, for all the reasons outsuch as MMF, namely patient and graft survival, are now regarded as being less useful in assessing these lined above, an agent which decreases the frequency and severity of rejection episodes, such as MMF, agents: survival rates are so high on conventional treatment (with 80-90% 1-year graft survival) that it seems likely to improve the lifespan of a renal allograft. is difficult to perform a trial of sufficient power to detect differences of the magnitude expected in interventions of this nature. For this reason, surrogates for graft survival have been sought, and acute rejecAdverse effects tion is one commonly used index.29
Rejection is the principal cause of graft loss and The principal adverse effects of MMF reported in the transplantation studies are gastrointestinal (especially early acute rejection has been recognized as 'by far the most powerful predictor of graft loss',43 including diarrhoea and vomiting), haematological and infective. In the European study,24 there was a small those losses due to chronic rejection. A study of 110 patients reported 1-year graft survival in three groups increase in each of these three categories of adverse effects compared with those patients on placebo. of patients-those without rejection, those with steroid-sensitive rejection, and those with steroidThe marginal benefits on the incidence of rejection of using the higher dose (3 g/day) of MMF over the resistant rejection-of 96%, 88% and 58% respectively.44 A review of 2322 transplant recipients lower dose (2 g/day) were outweighed by increased adverse effects. The incidence of all gastrointestinal, demonstrated that the 1-year survival of those who suffer early acute rejection was 67%, compared with haematological and opportunistic infective complications in the MMF 2-g/day group were 46%, 26% 86% for those who had no rejection.45 In an analysis of 603 patients, Naimark and Cole reported a 5-year and 38% respectively, compared with 42%, 13% and 28% in the placebo group. graft survival of 67% in those who had experienced an early episode of graft rejection, compared with
In the two studies in which MMF was compared with azathioprine, there was less variation in adverse 86% in those who had not.46 A study of 219 patients considered the data in a different way, reporting that effects between the MMF and control (azathioprine) groups. The US Study26 reported that opportunistic chronic rejection occurred in only 1/130 patients who had not experienced acute rejection, and 25/89 infections occurred in 46% patients in the azathioprine group and 45% and 47% patients in the who had.47 Another report suggested that only 2.5% of patients who had been free of acute rejection two MMF groups. There was, however, more tissueinvasive CMV infection in the two MMF groups, in eventually developed chronic rejection, compared with 12.5% of those who had suffered a single a dose-related pattern. Gastrointestinal adverse effects were more common in the MMF groups, but episode of acute rejection and 40% in those who had more than one episode.43 This group reported a very rarely led to discontinuation of the drug. Three patients developed lymphoma or lymphoproliferative half-life for graft survival of 16.9 years of those kidneys which had been rejection-free, but only 3.9 disease compared with none in the azathioprine group. Neutropenia was more common in the MMF years in the group which had experienced more than one rejection episode. Focusing on chronic loss, group (4-5% vs. 2% on azathioprine). In the Tricontinental Study,25 leucopenia and Matas et al. calculated graft half-lives on the basis of studying all grafts still functioning at 1 year.48 gastrointestinal disorders were more frequent in the MMF groups, and thrombocytopenia, thromThey reported a half-life of 46 years in patients who had suffered no acute rejection, 25 years in those bophlebitis and metabolic disorders were more frequent in the azathioprine group. However, infections who had suffered one episode and 5 years in those who had suffered more than one.
occurred at similar frequencies in the three groups. Importantly, there was no difference in the incidence Recent data have suggested that it is not merely the number, but also the severity of an acute rejection of tissue-invasive CMV infection between the MMF 2-g/day group and the azathioprine group. The episode which affects the prognosis.49 In grafts which On the basis of the three large studies described 
